The Medical Letter on Drugs and Therapeutics
FROM
ISSUE 1561
ISSUE 1561
December 3, 2018
Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
| Subscribers: Log in to read full article. Not a subscriber? Subscribe or purchase article. |
December 3, 2018 (Issue: 1561)
The FDA has approved sodium zirconium cyclosilicate
(Lokelma – AstraZeneca), an oral potassium binder that
exchanges hydrogen and sodium for potassium in the
gastrointestinal (GI) lumen, for treatment of non-life-threatening
hyperkalemia in adults. Sodium zirconium
cyclosilicate (SZC) is the third drug to be approved
for this indication; sodium polystyrene sulfonate and
patiromer (Veltassa) were approved earlier.
... more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.
Would you like to read the rest of this article? Gain access below.
Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
- Print version published and mailed biweekly (26 issues/year)
- Unlimited online access to current and past issues (1988 - present)
- Mobile App for iOS, Android, and Kindle Fire
- FREE online per issue CME/CE
Purchase this article:
Title: Sodium Zirconium Cyclosilicate (Lokelma) for Hyperkalemia
Article code: 1561c
Electronic, downloadable article - $45
Article code: 1561c
Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian
